The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.
A 23-year-old male with early stage 4 hair loss is using a treatment routine that includes minoxidil 5% with tretinoin once daily, finasteride 1mg every other day, 2.5mg oral minoxidil every other day, and derma rolling twice a week. The discussion is about whether using minoxidil twice a day is better than combining it with tretinoin once a day.
A user noticed a color change in their hair loss solution containing minoxidil, finasteride, retinoic acid, and hydrocortisone after storing it for several months. They are concerned about the effectiveness of the solution due to potential oxidation.
How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.
A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.
A 33-year-old user has been on finasteride for 10 years with great results and recently increased their oral minoxidil dose to 5 mg to improve hair thickness and possibly regrow hair. They are considering microneedling and a hair transplant to enhance their hairline and temples, despite already having significant improvement.
The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
The user reports that their hair loss treatment with oral minoxidil, dutasteride, finasteride, topical minoxidil, ketoconazole shampoo, and microneedling has plateaued, with no significant additional regrowth. They have stopped using creatine to simplify their regimen and are relieved with the current state compared to before treatment.
A user shared their positive experience with a 2987 graft hair transplant focused on the hairline, supplemented by finasteride and minoxidil for the mid scalp and crown. They expressed satisfaction with the results and the supportive care received during and after the procedure.
The user experienced high estradiol levels after using topical finasteride at 0.1 mg/day, which normalized after discontinuation. They are questioning if this low dosage could significantly impact hormone levels.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
Oral minoxidil was ineffective for OP, causing hair loss and unwanted body hair, while topical minoxidil showed significant regrowth. OP is switching to topical minoxidil with glycerin due to scalp issues with propylene glycol.
The conversation discusses confusion about how Minoxidil promotes hair growth compared to other substances like Menthol, which have similar actions. The user mentions personal positive results with peppermint oil extract and is currently trying L-citrulline for its vasodilation effects.
A user shares their hair loss treatment regimen, which includes oral finasteride, oral and topical minoxidil, RU58841, LLLT cap, microneedling, ketoconazole shampoo, biotin, vitamin D3, NAC supplement, MK677, collagen, and other hair care products. They seek opinions on its effectiveness.
OP is considering making a 5% topical Clascoterone (Breezula) for hair loss, as they use Minoxidil but can't use Finasteride due to side effects. They seek advice on creating the topical safely, possibly with help from a trained chemist.
A user questions if a topical compound with finasteride, dutasteride, minoxidil, retinoic acid, caffeine, and triamcinolone is excessive for hair loss treatment. Another user shares their experience using topical finasteride without issues and notes that alternating finasteride and dutasteride is common.
The user has been using a hair loss treatment regimen including RU58841, minoxidil, and dutasteride, but still experiences hairline recession and fatigue despite high testosterone levels. They are considering adjusting their dutasteride dosage due to concerns about libido and energy levels.
The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.
A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.
The user is asking if it's safe to use a glass dropper from a finished RU58841 product with a new RU58841 product and if cleaning it with water is sufficient. They are concerned about the quality of the plastic dropper that came with the new product.
The conversation is about using microneedling for hair loss treatment, including questions on disinfection and post-treatment care. The user mentions using oral minoxidil and finasteride, and considering dutasteride.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.
The user switched from minoxidil to a homemade 2-deoxy-d-ribose gel and noticed no hair fall after two weeks, despite stopping minoxidil. The gel includes water, 2-deoxy-d-ribose, vegetable glycerine, 2-phenoxyethanol, sodium alginate, and rosemary oil, and the user reports healthier-feeling hair.